Vicarious Surgical, Inc. · OTC:RBOT

Vicarious Surgical — SPAC Merger (April 2021)

32 slides from Vicarious Surgical's SPAC merger presentation, April 2021

  1. Slide 1: Investor Presentation April 2021

    INVESTOR PRESENTATION APRIL 2021 VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation is being furnished solely for the purpose of considering a potential transaction business combination disrupts Vicarious’ current plans and operations and potential difficulties in This document is being distributed solely for the consideration of sophisticated prospecti

  3. Slide 3: Today's Presenters

    TODAY’S PRESENTERS HOLDINGS CORP. CO-FOUNDER AND PRESIDENT CO-FOUNDER AND CEO EXECUTIVE CHAIRMAN CHIEF FINANCIAL OFFICER DONALD TANG ADAM SACHS DAVID STYKA BILL KELLY VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 00 | SUMMARY PRIVATE AND CONFIDENTIAL 3

  4. Slide 4: Transaction Summary

    TRANSACTION SUMMARY Vicarious is preparing to go public through a TRANSACTION STRUCTURE VALUATION business combination with D8 and is raising • Vicarious and D8 announced a • $1.1 billion post-money enterprise $115 million1 through a PIPE definitive business combination value; 3.1x 2025E revenue mul

  5. Slide 5: Key Investment Highlights

    KEY INVESTMENT HIGHLIGHTS NEXT GENER ATION ROBOTICS ABILITY TO ADDRESS MOST TECHNOLOGY ABDOMINAL PROCEDURES DESIGNED TO SOLVE MANUAL DEVELOPED IN STEALTH BY AND ROBOT-ASSISTED VISIONARY MANAGEMENT TEAM SURGERY SHORTCOMINGS AND INVESTORS TAPPING INTO A $136B ONLY ROBOT WITH FDA MARKET; 96.8% UNADDRES

  6. Slide 6: Our Team and Investors

    01 OUR TEAM AND INVESTORS VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 6

  7. Slide 7: Visionary Management Team

    VISIONARY MANAGEMENT TEAM CHIEF FINANCIAL OFFICER GENERAL COUNSEL AND CHIEF LEGAL OFFICER BILL KELLY JUNE MORRIS CO-FOUNDER, CHIEF VP OF SOFTWARE VP OF SYSTEMS MEDICAL OFFICER NEERAJ MAINKAR DAVE WILKINSON BARRY GREENE CO-FOUNDER AND CEO CO-FOUNDER AND CTO EXECUTIVE CHAIRMAN ADAM SACHS SAMMY KHALIFA

  8. Slide 8: Experienced Board and Advisors, Seasoned Investors

    EXPERIENCED BOARD SEASONED AND ADVISORS INVESTORS SELECT EXISTING INVESTORS EXECUTIVE CHAIRMAN D8 BOARD DIRECTOR­1 BOARD DIRECTOR BOARD DIRECTOR BOARD DIRECTOR DAVID STYKA DAVID HO PHIL LIANG ADAM SACHS RIC FULOP Bill Gates Noted HIV/AIDS Former Operational Researcher; Time “Man of Leader at Auris t

  9. Slide 9: The Problem

    02 THE PROBLEM VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 9

  10. Slide 10: The State of Surgery Today

    THE STATE OF SURGERY TODAY TROCAR SIZE VICARIOUS SURGICAL EXISTING SINGLE ROBOTS 4 1.5CM 2.5CM PORT ROBOTS THE BEGINNING ONE STEP FORWARD ONE STEP BACKWARD STUCK AT THE BEGINNING OPEN MINIMALLY- EXISTING OPEN SURGERY INVASIVE SINGLE-PORT SURGERY SURGERY ROBOTS DOMINANCE Manual and Robotic Large inci

  11. Slide 11: Limitations of Robotic Surgery Today

    LIMITATIONS OF ROBOTIC SURGERY TODAY HIGH COST DIFFICULT TO USE LIMITED CAPABILITIES LOW UTILIZATION THESE LIMITATIONS RESULT IN ONLY Capital and service costs Steep learning curves and Ill-suited for many outpatient Large profile, limited portability, 3.2% >$2M investment device-specific training p

  12. Slide 12: Our Solution

    03 OUR SOLUTION VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 12

  13. Slide 13: Our Solution

    VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 03 | OUR SOLUTION PRIVATE AND CONFIDENTIAL 13

  14. Slide 14: The System

    THE SYSTEM 3D SCREEN PROPRIETARY 9 1.5cm 360 SOFTWARE TROCAR SIZE EXISTING SINGLE DEGREES OF SINGLE DEGREES PORT ROBOTS SURGEON VICARIOUS SURGICAL FREEDOM PER ARM INCISION 1 VIEW ROBOT CONSOLE 5-10x 7 1.5CM 1 2.5CM LOWER YEARS CAPITAL COST 2 OF R&D 30+ 34” wide 28 PATIENT CART PATENTS ISSUED FITS TH

  15. Slide 15: Less Invasive While Maximizing Capabilities

    LESS INVASIVE WHILE MAXIMIZING CAPABILITIES INCISION MOTION REACH VISIBILITY MOBILITY ONE 1.5CM 1 TROCAR HUMAN EQUIVALENT ANYWHERE 2 EVERYWHERE 2 PORTABLE VIDEO LINK VIDEO LINK 2 robotic arms and 1 camera through 9 degrees of freedom per arm Unprecedented dexterity through Natural view in any and al

  16. Slide 16: Size

    SIZE Simple, portable, and capable—the Vicarious Surgical robot fits through a standard door and can fit into surgical facilities without construction buildout VICARIOUS SURGICAL ROBOTS LEGACY SURGICAL ROBOTS VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 03 | OUR SOLUTION PRIVATE AND CONFIDENT

  17. Slide 17: 360° Reach and View

    360° REACH AND VIEW The Vicarious Surgical robot can work anywhere in the abdomen through a 1.5cm1 incision The 9 decoupled actuators in each arm provide unprecedented dexterity inside of an ultra thin support tube LIMITED L ARGE WORKING WORKING AREA AREA LEGACY SINGLE VICARIOUS PORT ROBOTS SURGICAL

  18. Slide 18: Sensing and Visualization

    SENSING AND VISUALIZATION 3D DEPTH MAPPING FULL MOTION FORCE SENSING TR ACKING + FEEDBACK AT EVERY JOINT 4K HIGH FR AME WIDE FOV AUTOFOCUS R ATE TONE ADJUSTING HEAD MOUNTED LIGHTING DISPL AY 1 [1] WHILE CAPABLE OF HEAD MOUNTED DISPL AY CURRENTLY, MAY REQUIRE CLINICAL DATA FOR 03 | OUR SOLUTION PRIVA

  19. Slide 19: Economics

    ECONOMICS Advanced engineering enables sterile portion to be disposable with competitive cost structure • 3D printed and injection molded parts with polymer fiber cables • Decoupled actuators enable polymer cables and parts, lowering part costs vs traditional manufacturing over 5-10x1 • Enables ster

  20. Slide 20: Market Research Features

    MARKET RESEARCH 1| 360º REACH PROVIDES ACCESS TO ENTIRE ABDOMEN FEATURES 2| FULLY ARTICULATING JOINTS ALLOW FOR 9 DEGREES OF FREEDOM Surgeons and administrators reacted positively to the features that our surgical robot provides. Their favorite features are 3| REAL-TIME 4K 3D VISUALIZATION WITH uniq

  21. Slide 21: Market Research Competitor Comparison

    MARKET RESEARCH COMPETITOR COMPARISON 5 | Major Breakthrough VERY EASY SELL Independent blinded study with surgeons and 4.8 hospitals shows over 4 out of 5 score (very easy sell), well above competing solutions 4 | Important Advance STRONG SELLING POSITION COMPARED TO MANUAL MINIMALLY INVASIVE SURGE

  22. Slide 22: FDA Designated Breakthrough Technology

    FDA DESIGNATED BREAKTHROUGH TECHNOLOGY Our product is the only surgical robot to Agreement for clearance with receive a breakthrough designation from prioritized review3 the FDA indicating that they agree with our product’s potential for clinical benefit1 Hospital reimbursement may be higher for usi

  23. Slide 23: Our Pathway to Commercialization

    04 OUR PATHWAY TO COMMERCIALIZATION VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 23

  24. Slide 24: Expected Roadmap

    EXPECTED ROADMAP V&V Cadaver Study Complete Summative Usability Testing/ Cadaver Simulated Use Complete First V1.0 Unit Built Verification & Validation Complete Beta 1 Beta 2 Verification & FDA 510(k) Submission for DEVELOPMENT AND REGULATORY Validation Start Ventral Hernia Repair Filing FDA Presubm

  25. Slide 25: Regulatory Strategy

    VENTRAL HERNIA REGULATORY Initial launch of core product offering focused STRATEGY on 360º access and visualization for Ventral Hernia repair Verification and 510(k) Our regulatory strategy enables expedited Validation Filing filing while reducing risk by adopting a phased and scalable approach 510(

  26. Slide 26: Our Market, Our Potential

    05 OUR MARKET, OUR POTENTIAL VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL 26

  27. Slide 27: First Indication: Ventral Hernia

    FIRST INDICATION: VENTRAL HERNIA MARKET SIZE 1 EXISTING MEDICARE OUR FUNDAMENTAL ADVANTAGE REIMBURSEMENTS CMS provides an “unfettered path to coverage, beginning as soon as the same day as FDA market authorization for breakthrough devices”2 0.9M 3.3M US VENTRAL OUTSIDE US MEDICARE REIMBURSEMENT FOR

  28. Slide 28: Addressable Procedures

    INITIAL ADDRESSABLE ~11.5M 39M MARKET GALLBLADDER ABDOMINAL PROCEDURES 4 PROCEDURES ADDRESSABLE BY (~2.3M US) VICARIOUS 7 ~7.0M ALL OTHER ADDRESSABLE PROCEDURES TOTAL INITIAL HERNIA 3 ADDRESSABLE MARKET $136B (~1.5M US} ~13.4M 6 GI PROCEDURES 5 ~4.1M (~2.8M US) ~2.7M VENTRAL HYSTERECTOMY 2 HERNIA 1

  29. Slide 29: Financial Projections

    REVENUES & GROSS MARGIN FINANCIAL 1,200 100 SERVICE AND DISPOSABLES REVENUE PROJECTIONS 1,000 80% 79% 80% 83 78% 80% SYSTEM REVENUE 800 66 GROSS MARGIN GROSS MARGIN % REVENUE $M 600 50 Significant revenue potential with modest adoption: $1bn in revenue by 2027 with under 400 33 1% adoption 200 16 Gr

  30. Slide 30: Select Public References

    SELECT PUBLIC REFERENCES ENTERPRISE EV/REVENUE EV/REVENUE REVENUE CAGR VALUE 2024E 2025E 1 2023E-2025E 1 HIGH GROWTH MED-TECH - 10.2x 10.4x 23.1% - 16.3x 13.5x 22.0% DISRUPTIVE HC TECHNOLOGIES OTHER SURGICAL ROBOTICS $92.0B 12.1x 11.1x 11.9% VICARIOUS SURGICAL $1.1B 8.4x IMPLIED MULTIPLE 3.1x IMPLIE

  31. Slide 31: Transaction Overview

    TRANSACTION OVERVIEW Vicarious is preparing to go public through a ($ IN MILLIONS EXCEPT FOR SHARE PRICE) PRO FORMA OWNERSHIP 2 business combination with D8 and is raising SOURCES $115 million1 through a PIPE to further support Vicarious Rollover Equity $1000 long-term development plans D8 Cash Held

  32. Slide 32: Thank You

    THANK YOU VICARIOUS SURGICAL 78 Fourth Avenue vicarioussurgical.com Waltham, MA, 02451 +1.617.868.1700 VICARIOUS SURGICAL INVESTOR PRESENTATION APRIL 2021 PRIVATE AND CONFIDENTIAL

Vicarious Surgical — SPAC Merger (April 2021) on 6ix